**: The home of instruments.
On December 12, 2023, Suzhou Navitas Life Science and Technology Co., Ltd., a holding subsidiary of Suzhou Navitas Technology Co., Ltd. (688690), and Nanjing Adima Technology Co., Ltd. (hereinafter referred to as "Addis") reached a strategic cooperation agreement, under which the two parties established a joint laboratory to jointly develop new magnetic extraction materials and new detection technologies to solve the problems of clinical chromatography mass spectrometry automation, mass spectrometry automation, High-throughput pre-processing and detection landing problems, providing one-stop solution platform services.
Jiang Biwang, Chairman of Navitas Technology Group, Zhao Guangyao, General Manager of Navitas Life, and Shi Gongming, General Manager of Adimer Technology, attended the unveiling ceremony.
Break through the dilemma of small molecule clinical testing
The common small molecule substances in the human body include physiological hormones, vitamins, biogenic amines, biotoxins, serotonin, bile acids, amino acids, drugs, etc. Small molecule detection is of great significance in the field of clinical medical diagnosis, and with the deepening of small molecule research, its clinical application is becoming more and more extensive.
Because small molecule substances are not immunogenic, and most of them have only one epitope, it is difficult to produce high-affinity and high-specificity antibodies through direct immunization, and they are easily interfered with by analogues. Due to the limitations of the methodological shortcomings of the competition law itself, such as lack of precision, insufficient accuracy, susceptibility to interference, and narrow linear range, there are many limitations and controversies in its clinical application.
As the gold standard for small molecule detection, chromatography-mass spectrometry has excellent specificity and accuracy, but its wide use is limited due to the complexity of pretreatment methods, the absence of standard solutions for multi-item detection, and the high requirements for equipment and personnel. However, in the face of the continuous expansion of clinical demand, global diagnostic companies such as Roche have entered the game.
In this context, Navitas Life and Adimed Technologies have combined their respective technical advantages and clinical protocol development experience to establish a joint laboratory to focus on breaking through the dilemma of clinical small molecule testing, developing a variety of detection technologies that take into account the advantages of both immunological methods and chromatography mass spectrometry methods, and using intelligent magnetic bead extraction technology to solve the complex and standardized problems of clinical chromatography mass spectrometry pretreatment, especially to inject new life into the clinical mass spectrometry track facing development bottlenecks.
In order to provide better technical solution support for domestic and foreign IVD companies quickly and with high quality, Navitas Adimer Joint Laboratory fully meets the needs of customers by integrating upstream and downstream resources such as clinical chromatography and mass spectrometry, integrating pre-processing units, separation and extraction units, and detection units, accelerating the market access threshold to the greatest extent, and providing a truly mature and stable one-stop solution service platform for end-to-end small molecule chromatography mass spectrometry detection.
Dr. Shi Gongming said: "Now many major IVD manufacturers have entered the field of clinical chromatography mass spectrometry, and the industry is about to enter the era of high-throughput and low-cost assembly line testing. According to the clinical diagnosis needs and application characteristics, the R&D team of Adima has developed a clinical special chromatography mass spectrometry automatic detection system scheme by using intelligent magnetic extraction material preparation technology and automatic auxiliary equipment technology, and worked with Navitas Life to improve the application scheme of magnetic extraction materials for chromatography mass spectrometry to solve the current limitations of organic solvent contact, nitrogen blowing contamination risk, time-consuming and laborious, and low throughput in the process of clinical chromatography mass spectrometry sample processing. ”
Talking about the core advantages of magnetic extraction microspheres, Dr. Zhao Guangyao said: "Our magnetic beads are monodisperse microspheres, and they are rigid and not easy to produce fragment impurities, which will not affect the subsequent detection, and the accuracy of chromatography mass spectrometry quantitative detection is high. Only homogeneous and high-strength microspheres can guarantee the accuracy of the results. ”
Empower the 10 billion small molecule clinical testing market
The multi-series one-stop clinical chromatography mass spectrometry detection solution reserve has enabled both parties to have an excellent market response. It is understood that at present, Navitas Life and Adima have provided relevant products or solution support to nearly 100 customers, laying a solid foundation for the next one-stop clinical chromatography mass spectrometry detection solution - CRDMO platform for both parties.
In the face of the huge potential of the small molecule detection market, Dr. Shi Gongming introduced: "Our joint laboratory currently has a series of solutions including solid phase extraction chromatography packing materials, magnetic solid phase extraction materials, solid phase extraction systems for biological matrix samples, multi-dimensional liquid chromatography systems, etc., which can be widely used in clinical drug monitoring, vitamins, hormones, biogenic amines and other in vitro diagnostic projects, each segment corresponds to a huge market of nearly 10 billion. Adima has also made a good application demonstration in clinical clients, and together with Navitas Life, we can better provide solution support for our IVD companies. ”
Dr. Zhao Guangyao also expressed full confidence in the joint laboratory platform, saying: "This joint laboratory combines the strengths of Navitas Life and Adima Technology, and combines Navitas' technical accumulation and experience in the field of clinical diagnostic materials with Addison Technology's automated application material solution technology in the field of clinical chromatography mass spectrometry detection, and integrates the upstream and downstream industry chain to achieve 1+With the effect of 1 greater than 2, we will jointly launch the most cost-effective overall solution for small molecule testing of clinical chromatography mass spectrometry, bringing new life to the entire industry at the fastest speed. ”
Compared with the fully automatic pipeline clinical biochemical and chemiluminescence immunoassays, it is believed that Navitas&Edimaid's one-stop detection solution platform, using the fully automatic high-throughput rapid detection technology that takes into account the advantages of both immunological methods and chromatography mass spectrometry methods, can quickly inject new momentum into the clinical small molecule chromatography mass spectrometry detection industry and help the national precision medicine.